06.11.2023 21:56:50
|
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 06 November 2023 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2023 of DKK 30 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 4.1 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 November 2023 and ending on 29 January 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Instagram, X, LinkedIn and
YouTube.
Contacts for further information
Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Elizabeth DeLuca (US) +1 609 580 9868 edel@novonordisk.com |
Investors: | |
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US)
+1 848 213 3219 mjhr@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 72 / 2023
Attachment


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordiskmehr Nachrichten
20.03.25 |
Schwacher Wochentag in Europa: STOXX 50 nachmittags leichter (finanzen.at) | |
20.03.25 |
Schwacher Wochentag in Europa: STOXX 50 notiert mittags im Minus (finanzen.at) | |
20.03.25 |
Handel in Europa: STOXX 50 zum Start mit Zuschlägen (finanzen.at) | |
19.03.25 |
Börse Europa: STOXX 50 notiert zum Handelsende im Plus (finanzen.at) | |
19.03.25 |
Gewinne in Europa: STOXX 50 klettert am Mittwochnachmittag (finanzen.at) | |
19.03.25 |
Handel in Europa: STOXX 50 in der Gewinnzone (finanzen.at) | |
19.03.25 |
Zurückhaltung in Europa: STOXX 50 zum Start des Mittwochshandels in Rot (finanzen.at) | |
18.03.25 |
STOXX 50-Handel aktuell: STOXX 50 verbucht zum Handelsende Zuschläge (finanzen.at) |
Analysen zu Novo Nordiskmehr Analysen
17.03.25 | Novo Nordisk Buy | UBS AG | |
14.03.25 | Novo Nordisk Buy | UBS AG | |
12.03.25 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
11.03.25 | Novo Nordisk Buy | Deutsche Bank AG | |
11.03.25 | Novo Nordisk Underperform | Jefferies & Company Inc. |
Aktien in diesem Artikel
Novo Nordisk | 72,50 | -0,74% |
|